Chinese authorities are reportedly considering restrictions on overseas access to advanced AI models, including those developed by Deepseek, according to a report by The Wall Street Journal. Officials led by China’s Ministry of Commerce have held discussions with leading tech firms regarding potential controls on both closed-source and open-source systems. These measures reflect Beijing's growing view of cutting-edge AI as a strategic national asset, with export limits likely to increase costs for businesses relying on China's low-cost models.

The proposed measures include making the leak or theft of proprietary AI technology a national security offense and exploring limits on funding for domestic AI startups. These restrictions are currently under discussion and may apply only to future AI models, with no guarantee of implementation.

Strategic Implications for Global Markets

The potential export curbs signal a significant shift in how China manages its technological assets. By limiting access to advanced models, Beijing aims to maintain control over its AI capabilities while mitigating security risks. This move could alter the competitive landscape for global enterprises that have adopted Chinese AI solutions for their cost-effectiveness.

Expert opinions remain divided on the impact of Chinese AI models. While some analysts warn that China's low-cost, open-source models could reduce enterprise AI spending, others reject the notion that U.S. enterprises would switch to Chinese models.

Senator Rick Scott called on the Trump administration to increase tariffs on Chinese generic drug manufacturers, citing alleged forced labor practices and concerns about pharmaceutical safety. Scott argued that stronger trade measures are necessary to address human rights violations and protect American patients from potentially dangerous medications.

In a post on X, Scott criticized China's pharmaceutical industry, stating that the U.S. must act to stop human rights abuses. He specifically alleged that the industry utilizes Uyghur forced labor and produces generic drugs that are more dangerous than those manufactured domestically. The Senator emphasized the need to hold the entities involved accountable.

Trade and Security Context

The request for increased tariffs occurs amidst heightened scrutiny regarding U.S.-China pharmaceutical ties. Last month, bipartisan U.S. lawmakers launched national security reviews into Merck & Co. Inc. and AbbVie Inc. The lawmakers, led by Representative John Moolenaar, requested details on the companies' data security and research practices concerning clinical trials in China, citing potential risks to sensitive U.S. biotechnology research.

Despite the scrutiny, the lawmakers noted there was no evidence of wrongdoing by either company. The reviews focus on due diligence and the potential exposure of intellectual property and ethical standards in foreign trials.

Recent Trade Developments

The push for higher tariffs contrasts with trade adjustments observed in 2025. China reportedly eased some trade restrictions by exempting select U.S. imports, including certain pharmaceutical products and aerospace components, from 125% tariffs. Chinese officials sought feedback from businesses regarding other essential U.S. goods that could qualify for exemptions.

According to the American Chamber of Commerce in China, several pharmaceutical companies had already benefited from this tariff relief. The dynamic highlights the fluctuating nature of trade relations between the two nations in the healthcare sector.